Information Mediary Corp

Compliance Papers

URL Bridging Clinical Investigators and Statisticians: Writing the Statistical Methodology for a Research Proposal

- J Investig Med. 2009 Dec; 57(8): 818–824.

Volume 17
Intent to treat analysis requires coherent data sets. Med-ic electronic adherence monitoring technology can provide the needed set of tools to assure objective adherence data recording, and enable targeted coaching of your patients during the clinical trial phase. The result are a significant lift in adherence (usually 10-15% lift in median adherence have been observed), improved patient retention, and more precise statistical evaluation. In fact, when adherence improvement is rolled into your study protocol, your sample size can decrease at least 20%, resulting in lower cost, faster endpoints and better confidence in your go/no-go decisions, or in case of adaptive trials, continuance or termination decisions.

Talk to IMC's experts about using these powerful objective adherence measurement tools during your planning phase, at absolutely no cost or obligation.


PDF Med-ic® AND THE PHASE 2 GO/NO GO DECISION? Volume 16
Patient compliance data can be highly effective in phase 2 post hoc analyses leading up to the go/no go decision regarding a move to phase 3. Once the phase 2 objectives of assessing safety, tolerability and effectiveness have been met, the question is whether or not to proceed to phase 3 with its considerable resource requirements.

PDF DEBLISTERING AND COMPLIANCE Volume 15
Health care providers have long known that patients are poorly compliant with recommended treatment, but the extent of non-compliance has only become apparent during the last two decades. An extensive literature now demonstrates that non-compliance is a problem in every area of health care.

PDF ARGUMENTS FOR PHASE III COMPLIANCE MONITORING Volume 14
Inertia is difficult to overcome. When IMC introduced the Med-ic® electronic compliance monitor (ECM) nearly a decade ago it represented the potential for a revolution in clinical trials.

PDF ROI WIDGET - RATIONALE Volume 13
Power, magnitude of treatment effect (effect size) and sample size interact to determine the signal-to-noise ratio (S/N) of a clinical trial. The object is to determine if the treatment groups differ significantly from each other.

PDF HOW IS Med-ic® BEING USED IN CLINICAL TRIALS? Volume 12
Electronic compliance monitoring (ECM) adds cost to a clinical trial but offers enormous returns on the investment (ROI). How?

PDF Med-ic® ECM: INCORPORATING THE TECHNICAL CONTROLS FOR 21 CFR Part 11 Volume 11
Compliance Electronic record keeping has to control for the possibility of data tampering. FDA 21 CFR Part 11 wa, s established in 1997 to govern the use of electronic records and electronic signatures.

PDF WHY IS WIRELESS IMPORTANT? Volume 10
Wireless data transmission is the key to an efficient, flexible information system. It is prerequisite to the development of increasingly comprehensive information and home care systems. Med-ic® and eCAP™ both support wireless data transmission and connectivity.

PDF Med-ic® AND WIRELESS INTERCONNECTIVITY Volume 9
With aging population demographics combined with spiralling health-care costs, cost-reducing measures are the order of the day. Many involve systems that combine existing strategies in novel ways to give cost savings. The key to such systems is wireless interconnectivity – the ability of the various elements to intercommunicate in real-time without physical connections.

PDF REMS OVERVIEW Volume 8
A Risk Evaluation and Mitigation Strategy (REMS) is an FDA-mandated approach to ensuring the safety of medications. The baseline for ensuring the safe use of prescribed medication is professional labelling. REMS applies to situations where professional labelling is considered inadequate to ensure the safe use of a drug or class of drugs.

PDF ELECTRONIC COMPLIANCE MONITORING AND ADAPTIVE TRIALS Volume 7
The classical approach to decision-making in clinical research is the randomized trial. Patients are assigned to treatment conditions according to sample sizes that are determined a priori by power calculations. The data are not analyzed until the end of the study, at which time assignment codes are typically broken. Most clinical trials employ the Intent to Treat strategy which involves keeping all patients enrolled in the trial to its end. Positive decisions as to drug efficacy generally cannot be made until the study has been completed. Due to the cost and time involved in recruiting and processing subjects, size determination is extremely important. Unfortunately, this relies on two parameters that are rarely available during the study of new drugs – within-subject variability and the estimated magnitude of experimental effect.

PDF POWER AND RETURN ON INVESTMENT Volume 6
"At some point, perhaps not in the far future, it will seem as wrong to run a clinical trial without compliance measurement as without randomization." B. Efron, Statistics in Medicine, 1998 (17), 249-250.
Of course we are all aware of the central role played by randomization in the clinical research process. Virtually all clinical research employs this technique. However clinicians are generally surprised to hear that the physical sciences get along quite nicely without randomization.

PDF HOW COSTLY ARE YOUR DATA? Volume 5
Clinical trial costs are spiralling out of control. Studies generally estimate the cost of bringing an Investigational new drug (IND) to market at $1B although there is considerable variability in such estimates. Data handling and pickup costs related to patient records account for a staggering 30 percent of drug development costs. This is just the beginning of the cost of non-compliance – for more details, refer to “Medication Non-Compliance”, “How Valid Are Your Clinical Trials Data?” and “Are Patient Reports Accurate?”

PDF PHARMACY AS A SIGNAL-TO-NOISE RATIO Volume 4
All research, including pharmacotherapy, may be viewed in terms of a signal to noise ratio (S/N). In administering a medication, the aim is to maximize the S/N. The signal is the desired clinical effect; the noise comprises a multitude of factors that interfere with, or obscure, the clinical effect. The clinical effect might be reduction in pain, control of seizures, reduction in white cell count, etc. Most of the myriad noise factors come under the category of 'individual differences' in response to medication. Gastrointestinal differences ranging from malabsorption to eating habits, differences in metabolism, concomitant use of alcohol and street drugs, body mass, level of activity, use of herbal remedies, and many other noise factors conspire to obscure the therapeutic effect (signal).

PDF ARE PATIENT REPORTS ACCURATE? Volume 3
The problem of having patients determine their own dosing during clinical trials is widely recognized. If data obtained in clinical trials where patients take medication once or twice a day are known to be inaccurate, it follows that data from patients taking medication intermittently over longer intervals will be even less accurate. Such studies generally rely on the patient recording the date and time of self-medication.

PDF HOW VALID ARE YOUR CLINICAL TRIALS DATA? Volume 2
It is widely accepted that patients participating in clinical trials are less than perfectly compliant with their medication regimens. The extent to which non-compliance affects the results of clinical trials is unknown. Several factors mitigate against the assessment of this phenomenon, principal of which is the lack of a methodology to monitor patient compliance in a non-invasive (ie: unbiased) way.

PDF MEDICATION NON-COMPLIANCE Volume 1
Health care providers have long known that patients are poorly compliant with recommended treatment. The extent of non-compliance has only become apparent during the last two decades. An extensive literature now demonstrates that non-compliance is a problem in every area of health care. Many non-compliance issues are in the area of clinical pharmacy. With rapid advances in the understanding of the biological bases of medical and psychiatric disorders, pharmacotherapy has become by far the predominant therapeutic approach.
 


Value Proposition

See Us At

Data & Technology in Clinical Trials USA 2017
Philadelphia
Feb 21 - Feb 22 2017
Differentiate with data. Use technology and patient insight to make trials your competitive advantage.
The 2017 Global Clinical Supplies Group Conference
Albuquerque, New Mexico
Apr 23 - Apr 26 2017
The Global Clinical Supplies Group (GCSG) is a forum for clinical supply professionals to share knowledge, best practices and engage in open discussion.
CPES2017
Toronto, Canada
May 24 - May 26 2017
CPES is Canada’s premier conference and trade show exhibition for printable, flexible and wearable electronics (PE). CPES2017 is the place for PE industrial companies and end-users to meet and discuss how they can work together to commercialize new products and applications. Academic researchers can discover how they can link their research to market needs and opportunities.
Interphex Japan 2017
Tokyo Big Sight
Jun 28 - Jun 30 2017
With more than 1,000 exhibitors, INTERPHEX JAPAN is the world's leading and firmly established B-to-B trade show specialized in Pharmaceutical R&D and Manufacturing.